Document:

EX-10.12

 Exhibit 10.12 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN 

IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM 

THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND 

(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

AMENDMENT No 5 
 to 

the License and Collaboration Agreement of 19th May 2015 

by and between 
 BioNTech SE 

and 
 Genmab A/S 

  
 1 

 This Amendment No 5 is made and entered into as of May
08th, 2020 (Amendment No 5 Effective Date) by and between BioNTech SE, a German corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany (Biontech) and Genmab A/S, CVR
no. 21023884, a Danish corporation having its principal office at Kalvebod Brygge 43, DK-1560 Copenhagen V, Denmark, (Genmab). 

(Biontech and Genmab each a “Party” and together the “Parties”). 

PREAMBLE 
 WHEREAS, Biontech and Genmab are parties
to a certain License and Collaboration Agreement of 19th May 2015 by and between BioNTech SE and Genmab A/S, as amended by the Amendment No 1 dated May 18, 2017, Amendment No 2 dated
August 4, 2017, Amendment No. 3 dated May 18, 2018 and Amendment No. 4 dated November 25th 2019 as well as a Side Letter dated January 8, 2016, a Side Letter No 2 dated May 13, 2016 (as amended by the Amendment No 1 to
Side Letter No 2 dated May 19, 2017 as well as Amendment No 2 to Side letter No 2 dated May 18, 2018), a Side Letter No 3 dated September 25, 2017 and Letter Agreement dated February 4, 2020 (jointly referred to as the
“Agreement); 
 WHEREAS, Biontech and Genmab wish to extend the Duration of Phase A as well as the date of yearly adjustment of the FTE
rate; 
 WHEREAS, Biontech and Genmab wish to include [***] as shared costs; 

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, and for good and valuable consideration the
receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree to amend the Agreement as follows: 
  

	 	1.	 Except as otherwise defined herein, the words and phrases in the Agreement shall have the same meaning in this
Amendment No 5. 

  

	 	2.	 Section 2.5 of the Agreement is deleted in its entirety and replaced by the below new Section 2.5
with retroactive effect from the Effective Date. 

 “2.5 Duration of Phase
A. The joint research and development activities in Phase A are scheduled for an initial term of [***] years starting on the Effective Date. The Parties shall discuss in good faith an extension of Phase A at the latest
[***] months before the end of the initial term, provided that any extension of Phase A shall require the written mutual agreement between the Parties.” 
  

	 	3.	 Section 7.2 of the Agreement is deleted in its entirety and replaced by the below new Section 7.2
with effect from the Amendment No. 5 Effective Date: 

 “7.2 FTE Rate. The Parties agree
that the [***] of either Party who performs research, Development, consultation or support work under any Research or Development Plan is [***]. Commencing upon April 1 2019 and upon every anniversary thereafter, the fee will be adjusted in
accordance with the percentage change over the applicable annual period in the [***].” 

  
 2 

	 	4.	 Section 8.6 of the Agreement is deleted in its entirety and replaced by the below new Section 8.6
with effect from the Amendment No. 5 Effective Date. 

 “8.6 [***]. The costs and expenses
of R&D representatives (including members of the Joint Research Committee, Joint Steering Committee, Joint Development Team members, scientists and Joint Commercialization Committee, patent attorneys, project managers) associated with [***]
under this Section 8 (“[***]”) shall [***] (Shared Costs). Shared Costs shall be those related to any [***] as of the 1st of July 2019 and until expiry or termination of this Agreement. For the sake of clarity: [***]. 

 

	 	5.	 Save as set forth in this Amendment No 5, all other terms and conditions of the Agreement shall remain in full
force and effect. 

  

	 	6.	 This Amendment No 5 may be signed in any number of counterparts with the same effect as if the signatures
to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of the Amendment No 5. 

  

	 	7.	 The Parties agree that this Agreement can be signed using a DocuSign® electronic signature. Such electronic
signature is the legally binding equivalent to a Party’s handwritten signature and it has the same validity, enforceability and meaning as a handwritten signature and the Parties hereby waive any objection to the contrary.

 IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this Amendment No 5 as of the Amendment No 5 Effective
Date. 
  

									
	For BioNTech SE:	 		 	Genmab A/S
					
	Date:	 	  
	 		 	Date:	 	  

					
	Signature:	 	  
	 		 	Signature:	 	  

					
	Print name:	 	  
	 		 	Print name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

  
 3EX-10.38

 Exhibit 10.38 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH ( i ) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
 This
document is an English translation of a document prepared in German. In preparing this document, an attempt has been made to translate as literally as possible without jeopardizing the overall continuity of the text. Inevitably, however, differences
may occur in translation and if they do, the German text will govern by law. 
 In this translation, German legal concepts are expressed in English
terms and not in their original German terms. The concepts concerned may not be identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. 

Lease No.: 20 – 0 3 5 1 – 1 – 

22nd Amendment to the Lease of 11./12.04.2005 

 

			
	 between
	  	 WISTA Management

GmbH Rudower Chaussee 17

12489 Berlin

		
		  	 VAT ID No.: [***]

		
	 and
	  	 JPT Peptide Technologies GmbH

Volmerstraße 5

12489 Berlin

 The Lease is amended from 01.06.2020 as follows: 
  

			
	 Extension

	 Building:
	  	 03.51, Volmerstraße 5-9

	 Premises:
	  	 1327 Office (17.82m2)

	 Rent office:
	  	 €9.38m2

  

													
	 Period:
	 	until 31.05.2020	 	 	from 01.06.2020
extended by	 	 	from 01.06.2020
total	 
	 Rental space
	 	 	1,522.87m	2 	 	 	17.82m	2 	 	 	1,540.69m	2 
	 Rent
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 monthly advances for:
	 				 				 			
	 Building utilities/building operating costs
	 				 				 			
	 - Heat supply
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Electricity supply general
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Water supply/sewage disposal
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Rainwater removal
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Refrigeration supply
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Gas supply
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Special media supply
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Cleaning
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Maintenance
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Other
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Infrastructure levy
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Technical building management
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 - Property tax
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 Subtotal advances utilities/operating costs:
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 Subtotal rent and advances utilities/OC:
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 plus the relevant value-added tax in force (currently 19%)
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 
	 Total amount
	 	€	[	***] 	 	€	[	***] 	 	€	[	***] 

			
	Berlin,	  	 Berlin, 13.05.2020
 [signatures]

	WISTA Management GmbH	  	JPT Peptide Technologies GmbH

  

			
	 List of Rental Spaces
	  	Appendix 1
	 Lessee: JPT Peptide Technologies GmbH, Volmerstraße 5
	  	

  

					
		 		 	Bilingual Key
			 
		 		 	DE-EN
			 
		 		 	 Geschoss – Floor

			 
		 		 	
Raum-Nr. – Room No.

			 
		 		 	 Nutzung – Use

			 
		 		 	 Fläche – Surface
area

			 
		 		 	 1. OG – First floor

			 
		 		 	 2. OG – Second floor

			 
		 		 	 3. OG – Third floor

			 
		 		 	 Büro – Office

			 
		 		 	 Labor – Laboratory

			 
		 		 	 Lager – Storage area
büroähnlich –
 office-like

			 
		 		 	 Summe – Total

			 
		 		 	
Flächenerweiterung ab 01.06.2020

– Expansion of area from 01.06.2020

 Anlage 1 

Aufstellung Mietflächen 
 Mieter: JPT Peptide
Technologies GmbH, Volmerstraße 5 
  

							
	 Geschoss
	  	 Raum-NR.
	  	 Nutzung
	  	 Fläche (m2)

	1.OG	  	1137	  	Büro	  	20,14
	1.OG	  	1138	  	Büro	  	23,97
	1.OG	  	1220	  	Büro	  	17,91
	1.OG	  	1222	  	Büro	  	17,78
	1.OG	  	1223	  	Büro	  	17,98
	1.OG	  	1224	  	Büro	  	17,78
	1.OG	  	1242	  	Labor	  	28,84
	1.OG	  	1239	  	Labor	  	29,11
	1.OG	  	1241	  	Labor	  	21,45
	1.OG	  	1243	  	Büro	  	15,05
	1.OG	  	1320	  	Büro	  	23,87
	1.OG	  	1322	  	Büro	  	17,91
	1.OG	  	1325	  	Büro	  	17,82
	1.OG	  	1326	  	Büro	  	17,98
	1.OG	  	1327	  	Büro	  	17,82
	1.OG	  	1328	  	Büro	  	17,98
	2.OG	  	2120	  	Büro	  	16,26
	2.OG	  	2121	  	Lager	  	18,20
	2.OG	  	2122	  	Labor	  	17,85
	2.OG	  	2123	  	Büro	  	23,82
	2.OG	  	2124	  	Büro	  	17,98
	2.OG	  	2126	  	Büro	  	11,79
	2.OG	  	2127	  	Büro	  	17,91
	2.OG	  	2128	  	Büro	  	11,79
	2.OG	  	2129	  	Lager	  	25,75
	2.OG	  	2130	  	Büro	  	14,09
	2.OG	  	2131	  	Büro	  	17,91
	2.OG	  	2132	  	Büro	  	39,43
	2.OG	  	2134	  	Büro	  	20,74
	2.OG	  	2135	  	Labor	  	21,17
	2.OG	  	2137	  	Labor	  	39,72
	2.OG	  	2138	  	Labor	  	22,09
	2.OG	  	2139	  	Labor	  	29,00
	2.OG	  	2140	  	Büro	  	17,73
	2.OG	  	2141	  	Labor	  	23,77
	2.OG	  	2142	  	Labor	  	25,59
	2.OG	  	2434	  	Labor	  	29,11
	3.OG	  	3120	  	Büro	  	17,85
	3.OG	  	3121	  	Lager	  	29,34
	3.OG	  	3122	  	Büro	  	17,91
	3.OG	  	3123	  	Büro	  	17,78
	3.OG	  	3124	  	Büro	  	17,98
	3.OG	  	3126	  	Büro	  	11,79
	3.OG	  	3127	  	Büro	  	17,91
	3.OG	  	3128	  	Büro	  	11,79
	3.OG	  	3129	  	Lager	  	25,75
	3.OG	  	3130	  	Büro	  	14,09
	3.OG	  	3131	  	Büro	  	17,91
	3.OG	  	3132	  	Labor	  	39,43
	3.OG	  	3134	  	Labor	  	20,74
	3.OG	  	3135	  	Labor	  	21,17
	3.OG	  	3137	  	Labor	  	39,72
	3.OG	  	3138	  	Labor	  	22,09
	3.OG	  	3140	  	Labor	  	29,05
	3.OG	  	3141	  	Labor	  	29,25
	3.OG	  	3142	  	Labor	  	28,85
	3.OG	  	3143	  	büroãhlich	  	13,38
	3.OG	  	3320	  	Labor	  	17,91
	3.OG	  	3321	  	Labor	  	17,82
	3.OG	  	3323	  	Büro	  	30,06
	3.OG	  	3325	  	Büro	  	24,10
	3.OG	  	3326	  	Büro	  	17,75
	3.OG	  	3327	  	Büro	  	17,85
	3.OG	  	3328	  	Labor	  	23,81
	3.OG	  	3329	  	Büro	  	11,73
	3.OG	  	3330	  	Labor	  	23,81
	3.OG	  	3332	  	Büro	  	17,69
	3.OG	  	3333	  	Büro	  	17,91
	3.OG	  	3335	  	Büro	  	15,12
	3.OG	  	3422	  	Büro	  	36,14
	3.OG	  	3424	  	Büro	  	22,30
	3.OG	  	3735	  	Büro	  	17,82
		  		  	Summe	  	1540,69
		
		  	Flãchenerweiterung ab 01.06.2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]